U.S. markets close in 3 hours 36 minutes

AstraZeneca PLC (AZN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
52.90-1.53 (-2.82%)
As of 12:24PM EST. Market open.

AstraZeneca PLC

1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
United Kingdom
44 20 3749 5000
http://www.astrazeneca.com

Sector(s)Healthcare
IndustryDrug Manufacturers—General
Full Time Employees70,600

Key Executives

NameTitlePayExercisedYear Born
Mr. Pascal Soriot D.V.M., M.B.A.CEO & Exec. DirectorN/AN/A1959
Mr. Marc DunoyerCFO & Exec. DirectorN/AN/A1952
Ms. Pam P. ChengExec. Vice-Pres of Operations & Information TechnologyN/AN/A1971
Thomas Kudsk LarsenHead of Investor RelationsN/AN/AN/A
Mr. Jefrey PottExec. VP of HR & Gen. CounselN/AN/AN/A
Ms. Katarina AgeborgExec. VP of Sustainability & Chief Compliance OfficerN/AN/AN/A
Dr. Menelas PangalosExec. Vice-Pres of BioPharmaceuticals R&DN/AN/AN/A
Dr. Ruud DobberExec. Vice-Pres of BioPharmaceuticals Bus. UnitN/AN/AN/A
Dr. Susan Mary GalbraithSr. VP and Head of Research, Early Devel. & Oncology R&DN/AN/A1966
Dr. David B. Goldstein Ph.D.Chief AdviserN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR/Komboglyze, Onglyza, Qtern, Symlin, Xigduo/Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Tudorza/Eklira, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, and Symbicort Turbuhaler for respiratory diseases; Fluenz Tetra/FluMist Quadrivalen and Synagis for infection diseases; Movantik/Moventig, Seroquel IR/Seroquel XR, and Vimovo for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Arcus Biosciences, Inc. to evaluate domvanalimab (AB154), an investigational anti-TIGIT antibody in combination with Imfinzi (durvalumab); Fusion Pharmaceuticals Inc. to develop and commercialize next-generation alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer; and Recombinetics Inc. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.

Corporate Governance

AstraZeneca PLC’s ISS Governance QualityScore as of January 22, 2021 is 7. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 10; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.